Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation

The designation was based on data generated from clinical trials with sebelipase alfa in patients with early onset LAL Deficiency.

http://www.drugs.com/clinical_trials/synageva-s-sebelipase-alfa-receives-breakthrough-therapy-designation-15562.html